Rapid Zika Virus Test Kit

This kit is used for invitro qualitative detection of SARS‐CoV‐2 antigen. Positive result from the test need further analysis with clinical history of patient and other diagnostic information to determine patient's infection status. Positive value is only a reference guide for clinical diagnosis. The test results only reflect the current state of the sample. Negative result cannot exclude SARS‐CoV‐2 infection and should not be used as the sole basis for patient's management decisions. Negative results must be combined with clinical observations, patient history, and epidemiolol information. This test is only for clinical laboratories, medical institutions use and for real‐time inspection by professional medical staff, and not for home testing. It cannot be used as the basis for the diagnosis and exclusion of pneumonia caused by SARS‐CoV‐2 and is not suitable for general population screening. The laboratory testing of SARS‐CoV‐2 should meet the requirements of the "Laboratory testing for SARS‐CoV‐2 in suspected human cases” and other requirements, and pay attention to the biosecurity.

Rapid test kit for malaria detect antigens or antibodies in the serum, plasma or blood through the use of species‐specific complementary markers in the test device. The Rapid test kit for malaria can detect the presence of both Plasmodium falciparum and Plasmodium vivax infection.

The viral transport medium consists of Hanks Balanced Salt Solution modified and enriched with bovine serum albumin, amino acid, gelatin peptone and carbohydrate. The pH is adjusted with buffer. Phenol red is used as a pH indicator. Vancomycin, amphotericin B and colistin have been added to the medium to inhibit the proliferation of competing bacteria and yeasts. The medium is isotonic and lacks toxicity to the mammalian host cells.